These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 8921822)

  • 1. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
    Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V; Freneau E; Morange I; Simonetta C
    Ann Endocrinol (Paris); 2000 Nov; 61(5):411-7. PubMed ID: 11084391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
    Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.
    Guido R; Valenti S; Foppiani L; De Martini D; Cossu M; Giusti M
    J Endocrinol Invest; 1997 May; 20(5):289-93. PubMed ID: 9258810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinagolide in the management of prolactinoma.
    Schultz PN; Ginsberg L; McCutcheon IE; Samaan N; Leavens M; Gagel RF
    Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW; Atkin SL; Savage MW; Masson EA; White MC
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
    Tabarin A; Catargi B
    Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Delgrange E; Crabbé J; Donckier J
    Horm Res; 1998; 49(5):250-3. PubMed ID: 9568811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine.
    Vilar L; Burke CW
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):821-6. PubMed ID: 7889620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinomas and resistance to dopamine agonists.
    Brue T; Pellegrini I; Priou A; Morange I; Jaquet P
    Horm Res; 1992; 38(1-2):84-9. PubMed ID: 1306523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactinomas and pregnancy.
    Bronstein MD
    Pituitary; 2005; 8(1):31-8. PubMed ID: 16411066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.